<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335045</url>
  </required_header>
  <id_info>
    <org_study_id>13-01-01</org_study_id>
    <nct_id>NCT04335045</nct_id>
  </id_info>
  <brief_title>Phase I Study of PH100 (Ecklonia Cava Phlorotannins)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PH100 Capsules in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phloronol Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phloronol Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety and tolerability of PH100, a purified&#xD;
      phlorotannins from a brown alga Ecklonia cava and the pharmacokinetics of its major compounds&#xD;
      8,8'-bieckol, dieckol, and phlorofucofuroeckol A (PFF-A), after single, ascending, oral doses&#xD;
      of PH100 Capsules (over-encapsulated tablets) in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single-center, randomized, double-blind, placebo-controlled, single ascending dose&#xD;
      study in healthy volunteers in which subjects received either placebo or a 100 mg, 200 mg,&#xD;
      400 mg, 800 mg, 1200 mg, or 1600 mg dose of PH100 capsules (over-encapsulated tablets&#xD;
      containing purified Ecklonia cava phlorotannins as an active ingredient) in escalating dose&#xD;
      groups (six cohorts). A total of 48 subjects were enrolled. Each cohort comprised eight&#xD;
      subjects. Within each cohort, six subjects received PH100 and two subjects received placebo.&#xD;
      The first cohort was dosed as a single group with PH100 (100 mg) or placebo. The subsequent&#xD;
      five cohorts were dosed sequentially with 200 mg, 400 mg, 800 mg, 1200 mg, and 1600 mg of&#xD;
      PH100 or placebo. Safety and pharmacokinetic data were collected and evaluated following each&#xD;
      cohort. Dose escalation occurred after review of the safety and pharmacokinetic data from the&#xD;
      preceding cohort(s). Doses were administered with subjects in the fasted condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2013</start_date>
  <completion_date type="Actual">December 8, 2014</completion_date>
  <primary_completion_date type="Actual">December 8, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single-center, randomized, double-blind, placebo-controlled, single ascending dose study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>96 hours postdose</time_frame>
    <description>Subjects were instructed to inform the study physician and/or research personnel of any AEs that occurred at any time during the study. Subjects were monitored for AEs from the beginning of confinement through the end-of-study visit (96 hours after dose administration). Reported or observed AEs were documented and followed to resolution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit (%)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin (g/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocytes (10^6/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukocytes (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basophils (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basophils/Leukocytes (%)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eosinophils (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eosinophils/Leukocytes (%)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocytes (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocytes/Leukocytes (%)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocytes (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocytes/Leukocytes (%)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophils (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophils/Leukocytes (%)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelets (10^3/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Glucose (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium (mmol/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potassium (mmol/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chloride (mmol/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood urea nitrogen (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urate (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin (g/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline phosphatase (U/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate phosphatase (U/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine transaminase (U/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total bilirubin (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate Dehydrogenase (U/L)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific gravity</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pH</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nitrite (Negative/Positive)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukocyte esterase (/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occult blood (/uL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urobilinogen (mg/dL)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Systolic Blood Pressure (mmHg)</measure>
    <time_frame>2, 4, 48, 96 hours postdose</time_frame>
    <description>Safety Assessment in Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Diastolic Blood Pressure (mmHg)</measure>
    <time_frame>2, 4, 48, 96 hours postdose</time_frame>
    <description>Safety Assessment in Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Pulse Rate (bpm)</measure>
    <time_frame>2, 4, 48, 96 hours postdose</time_frame>
    <description>Safety Assessment in Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Respiration Rate (Breath/Min)</measure>
    <time_frame>2, 4, 48, 96 hours postdose</time_frame>
    <description>Safety Assessment in Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Body Temperature (degrees C)</measure>
    <time_frame>2, 4, 48, 96 hours postdose</time_frame>
    <description>Safety Assessment in Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG heart rate (bpm)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PR interval (ms)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS complex (ms)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QT interval (ms)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcB interval (ms)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcF interval (ms)</measure>
    <time_frame>48 hours postdose</time_frame>
    <description>Safety Assessment in ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Concentration of 8,8'-bieckol (ng/mL) by HPLC-MS</measure>
    <time_frame>at 0, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 96 hours after dosing.</time_frame>
    <description>Pharmacokinetics of 8,8'-bieckol, a major compound of PH100, after single, ascending, oral doses (100 mg, 200 mg, 400 mg, 800 mg, 1200 mg, and 1600 mg) of PH100 in normal healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Concentration of dieckol (ng/mL) by HPLC-MS</measure>
    <time_frame>at 0, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 96 hours after dosing.</time_frame>
    <description>Pharmacokinetics of 8,8'-bieckol, a major compound of PH100, after single, ascending, oral doses (100 mg, 200 mg, 400 mg, 800 mg, 1200 mg, and 1600 mg) of PH100 in normal healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Concentration of PFF-A (ng/mL) by HPLC-MS</measure>
    <time_frame>at 0, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 96 hours after dosing.</time_frame>
    <description>Pharmacokinetics of 8,8'-bieckol, a major compound of PH100, after single, ascending, oral doses (100 mg, 200 mg, 400 mg, 800 mg, 1200 mg, and 1600 mg) of PH100 in normal healthy volunteers.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>100mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x 100 mg PH100 capsule (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control for 100mg Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo capsule (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x 200 mg PH100 capsule (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control for 200mg Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo capsule (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 200 mg PH100 capsules (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control for 400mg Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo capsules (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 x 200 mg PH100 capsules (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control for 800mg Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 placebo capsules (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 x 200 mg PH100 capsules (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control for 1200mg Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 placebo capsules (n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1600mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 x 200 mg PH100 capsules (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control for 1600mg Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 placebo capsules (n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1~8 Placebo capsule(s) corresponding to each PH100 dose</description>
    <arm_group_label>Control for 100mg Dose</arm_group_label>
    <arm_group_label>Control for 1200mg Dose</arm_group_label>
    <arm_group_label>Control for 1600mg Dose</arm_group_label>
    <arm_group_label>Control for 200mg Dose</arm_group_label>
    <arm_group_label>Control for 400mg Dose</arm_group_label>
    <arm_group_label>Control for 800mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH100 100mg</intervention_name>
    <description>1 x 100 mg PH100 oral capsule</description>
    <arm_group_label>100mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH100 200mg</intervention_name>
    <description>1 x 200 mg PH100 oral capsule</description>
    <arm_group_label>200mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH100 400mg</intervention_name>
    <description>2 x 200 mg PH100 oral capsules</description>
    <arm_group_label>400mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH100 800mg</intervention_name>
    <description>4 x 200 mg PH100 oral capsules</description>
    <arm_group_label>800mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH100 1200mg</intervention_name>
    <description>6 x 200 mg PH100 oral capsules</description>
    <arm_group_label>1200mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH100 1600mg</intervention_name>
    <description>8 x 200 mg PH100 oral capsules</description>
    <arm_group_label>1600mg Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or nonpregnant, nonbreastfeeding female;&#xD;
&#xD;
          -  Between 40 and 75 years of age (inclusive);&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and minimum weight of 50 kg&#xD;
             (110 lbs);&#xD;
&#xD;
          -  If female, subject was considered postmenopausal or surgically sterile and had status&#xD;
             confirmed by one of the following:&#xD;
&#xD;
          -  Physiologicallypostmenopausalbasedonnomensesforatleast2years(not due to lactational&#xD;
             amenorrhea) and follicle stimulating hormone (FSH) levels equal to or greater than&#xD;
             40.0 mIU/mL at screening; or&#xD;
&#xD;
          -  Bilateraloophorectomy,hysterectomy,orbilateraltuballigation(post 6 months). Or&#xD;
&#xD;
          -  If female and of childbearing potential, subject agreed to use one of the following&#xD;
             forms of birth control from 3 months prior through 12 days after study drug&#xD;
             administration:&#xD;
&#xD;
          -  Vasectomizedpartner(atleast6monthspriortodosing);&#xD;
&#xD;
          -  Doublebarrier(diaphragmwithspermicide;condomswithspermicide);&#xD;
&#xD;
          -  Intrauterinedevice(IUD);&#xD;
&#xD;
          -  Abstinence(agreedtouseadoublebarriermethodiftheybecamesexually active during the&#xD;
             study);&#xD;
&#xD;
          -  Implantedorintrauterinehormonalcontraceptives;or&#xD;
&#xD;
          -  Oral,patch,orinjectedcontraceptives,orvaginalhormonaldevice (i.e. NuvaRing®).&#xD;
&#xD;
          -  If male, subject had a documented vasectomy or agreed to use a double-barrier local&#xD;
             contraception (i.e., condom with spermicide) when engaging in sexual activity with&#xD;
             women of childbearing potential from prior to the first dose of study drug through 28&#xD;
             days after the last dose of study drug;&#xD;
&#xD;
          -  If male, subject agreed to refrain from sperm donation from prior to the first dose of&#xD;
             study drug through 28 days after the last dose of study drug;&#xD;
&#xD;
          -  Voluntarily consented to participate in this study and provided their written informed&#xD;
             consent prior to start of any study-specific procedures;&#xD;
&#xD;
          -  Able to communicate with the Investigator, and understand and comply with the&#xD;
             requirements of the protocol;&#xD;
&#xD;
          -  Willing and able to remain in the study unit for the entire duration of the&#xD;
             confinement period and return for an outpatient visit;&#xD;
&#xD;
          -  Had screening blood pressure (measured sitting after 3 minutes rest) 140/90 mmHg.&#xD;
             Out-of-range blood pressure could be repeated once; and&#xD;
&#xD;
          -  Willing and able to swallow up to eight size AAA capsules with water at dose&#xD;
             administration. Size AAA capsules are 0.642 inches (16.31 mm) in length and 0.450&#xD;
             inches (11.44 mm) in diameter).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, GI, endocrine (including thyroid), immunologic, dermatologic,&#xD;
             neurologic, oncologic, respiratory, lymphatic, musculoskeletal, genitourinary,&#xD;
             infective, inflammatory, connective tissue, or psychiatric disease or disorder or any&#xD;
             other condition that, in the opinion of the Investigator, would have jeopardized the&#xD;
             safety of the subject or the validity of the study results;&#xD;
&#xD;
          -  Clinically relevant history or presence of cardiac arrhythmia, narrow angle glaucoma,&#xD;
             benign prostatic hypertrophy (men only), Hashimoto's thyroiditis, lymphocytic&#xD;
             thyroiditis, or uncontrolled diabetes;&#xD;
&#xD;
          -  Had a clinically significant abnormal finding on the physical exam, medical history,&#xD;
             ECG, or clinical laboratory results at screening;&#xD;
&#xD;
          -  History or presence of allergic or adverse response to PH100 (product names:&#xD;
             Seapolynol, Fibroboost, Fibronol, Seanol Longevity Plus, Circulate, Alginol, PC&#xD;
             Ecklonia Cava, Seanol, Seanol-F, Seanol-EX, Seanol-TX, Venusen, Memories with&#xD;
             Seanol-P, Astaxanthol, Brilliant Vision with Seanol-P, Gly-Control, Gyne-Andro-Plex,&#xD;
             Lipid Balance, Seanol with Broccoraphanin, and Marine D3) or related drugs;&#xD;
&#xD;
          -  Had used PH100 (product names: Seapolynol, Fibroboost, Fibronol, Seanol Longevity&#xD;
             Plus, Circulate, Alginol, PC Ecklonia Cava, Seanol, Seanol-F, Seanol-EX, Seanol-TX,&#xD;
             Venusen, Memories with Seanol-P, Astaxanthol, Brilliant Vision with Seanol-P,&#xD;
             Gly-Control, Gyne-Andro-Plex, Lipid Balance, Seanol with Broccoraphanin, and Marine&#xD;
             D3) as a supplement within 30 days prior to the first dose of study medication;&#xD;
&#xD;
          -  Had been on a significantly abnormal diet during the 4 weeks preceding the first dose&#xD;
             of study medication;&#xD;
&#xD;
          -  Had donated blood or plasma within 30 days prior to the first dose of study&#xD;
             medication;&#xD;
&#xD;
          -  Had participated in another clinical trial (randomized subjects only) within 30 days&#xD;
             prior to first dose of study medication;&#xD;
&#xD;
          -  Had used any over-the-counter (OTC) medication, including nutritional supplements,&#xD;
             within 5 half-lives or 14 days (whichever was longer) prior to the first dose of study&#xD;
             medication;&#xD;
&#xD;
          -  Had used any prescription medication, except hormonal contraceptives for women of&#xD;
             childbearing potential or hormone replacement therapy, within 5 half-lives or 14 days&#xD;
             (whichever was longer) prior to the first dose of study medication;&#xD;
&#xD;
          -  Had ingested drinks or foods containing grapefruit or St. John's Wort within 14 days&#xD;
             prior to the first dose of study medication;&#xD;
&#xD;
          -  Had been treated with any known drugs that are moderate or strong inhibitors/inducers&#xD;
             of CYP enzymes such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc.,&#xD;
             within 30 days prior to the first dose of study medication and that in the&#xD;
             Investigator's judgment may have impacted subject safety or the validity of the study&#xD;
             results;&#xD;
&#xD;
          -  Had discontinued the use of implanted, intrauterine, or injected hormonal&#xD;
             contraceptives less than 6 months prior to the first dose of study medication;&#xD;
&#xD;
          -  Had discontinued the use of oral, patch, or vaginal hormonal contraceptives less than&#xD;
             1 month prior to the first dose of study medication;&#xD;
&#xD;
          -  Had smoked or used tobacco products within 6 months prior to the first dose of study&#xD;
             medication;&#xD;
&#xD;
          -  Had a history of substance abuse or treatment (including alcohol);&#xD;
&#xD;
          -  Was a female who had a positive pregnancy test result or was nursing, lactating, or&#xD;
             trying to become pregnant;&#xD;
&#xD;
          -  Had a positive urine screen for drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cocaine, cannabinoids, opiates), alcohol, or cotinine;&#xD;
&#xD;
          -  Had a positive test for hepatitis B surface antigen (HbSAg), hepatitis C antibody, or&#xD;
             human immunodeficiency virus (HIV) at screening or had been previously treated for&#xD;
             hepatitis B, hepatitis C, or HIV infection; or&#xD;
&#xD;
          -  Had difficulty swallowing up to eight capsules.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George J. Atiee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials Early Phase Services, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>PH100</keyword>
  <keyword>Ecklonia cava</keyword>
  <keyword>Phlorotannin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

